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In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility.
Using a genome-wide association study (GWAS) approach, we identified a genetic variant in TCERG1L (rs893507) to be associated
with hearing loss in 390 non-cranial irradiated, cisplatin-treated children with cancer. These results were replicated in two
independent, similarly treated cohorts (n= 192 and 188, respectively) (combined cohort: P= 5.3 × 10−10, OR 3.11, 95% CI 2.2–4.5).
Modulating TCERG1L expression in cultured human cells revealed significantly altered cellular responses to cisplatin-induced
cytokine secretion and toxicity. These results contribute to insights into the genetic and pathophysiological basis of cisplatin-
induced ototoxicity.
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Survival probabilities for pediatric cancer have increased tremen-
dously over the past decades1. Cisplatin is a highly effective
chemotherapeutic agent for an important subset of childhood
cancers that depend on this drug for curation. However, the
occurrence of irreversible hearing loss that occurs in ~50% of
cisplatin-treated children is a serious clinical challenge2,3. Young
age at cancer diagnosis, high total cumulative dose (TCD) of
cisplatin, cranial irradiation, and/or subsequent carboplatin use
might increase the risk of developing hearing loss4–6. Under-
standing the biology of cisplatin-induced hearing loss and
identifying risk factors that could predict ototoxicity is highly
relevant as children are at a critical stage of their speech and
language development, with the added risk of experiencing social,
emotional, or vocational difficulties related to hearing loss. This
ultimately impacts development and quality of life during
treatment but also later in life7.
The significant heterogeneity in the occurrence of ototoxicity
among similarly treated patients suggests that genetic suscept-
ibility contributes to cisplatin-related hearing loss8. Therefore, we
performed a GWAS in a discovery cohort of 390 cisplatin-treated,
non-cranial-irradiated European children with cancer (n= 168
(43.0%) with hearing loss, Supplementary Table 1)9. This cohort
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was assembled by the European initiative of the PanCareLIFE (PCL)
group (http://www.pancarelife.eu/)10. Cases were defined as
having deleterious hearing loss according to Muenster ≥2b after
the aforementioned treatment and were compared to subjects
with Muenster 0–2a (Supplementary Table 2)11. A two-stage
design GWAS was conducted consisting of one discovery cohort
and two replication cohorts (Supplementary Fig. 1). In the
discovery cohort, a logistic regression model was applied,
including age at diagnosis, sex, cisplatin TCD, and principal
components 1–4, with the assumption of an additive effect of the
minor allele in the model (Supplementary Tables 1 and 3, and see
the “Methods” section).
In the first stage, the discovery cohort (D) GWAS analysis
identified eight suggestive loci (P < 1.0 × 10−5; Table 1, and
Supplementary Figs. 1 and 2)12, which were assessed in a second
stage by pursuing replication of suggestive variants in a first,
independent Canadian replication cohort (R1) of non-cranial
irradiated, cisplatin-treated children (n= 192; 115 (59.9%) with
hearing loss) (Supplementary Tables 1 and 3, and Supplementary
Fig. 1)9. Rs893507 showed evidence of replication (P= 0.01),
resulting in a combined OR of 2.77, adjusted for age at diagnosis,
sex, cisplatin TCD, and principal components 1–4 (combined
analysis 1: P= 4.5 × 10−7, 95% CI 1.9–4.1; Table 1). This genetic
variant is located in an intron of the Transcription Elongation
Regulator 1 Like (TCERG1L) gene (Fig. 1, Supplementary Table 4).
This variant could potentially disrupt RNA splicing, resulting in loss
of exons, or in the inclusions of introns, with a subsequently
altered protein expression. Next, analysis in a second independent
replication cohort, consisting of PCL childhood cancer survivors
(R2) including 188 non-cranial-irradiated cisplatin-treated subjects
(94 (50.0%) with hearing loss), confirmed the findings observed in
the first replication cohort (Supplementary Tables 1 and 3, and
Supplementary Fig. 1)9.
Combined analysis of these three cohorts represents the largest
cohort to date of non-cranial irradiated, cisplatin-treated child-
hood cancer patients and survivors. Our results showed that the
genetic variant rs893507 was associated with deleterious hearing
loss at genome-wide significance. Carriership of the C-allele of this
newly discovered variant increases the odds of developing serious
cisplatin-induced hearing loss in children treated for cancer 3.11-
fold, adjusted for age at diagnosis, sex, cisplatin TCD, and principal
components (combined analysis 2: P= 5.3 × 10−10, 95% CI 2.2–4.5;
Table 1; Supplementary Fig. 3).
Although a specific cisplatin threshold dose associated with
ototoxicity has not been found previously13, an association was
observed between deleterious hearing loss and cisplatin TCD
continuously (OR 1.35, 95% CI 1.1–1.5) as well as after stratification
(360–480 mg/m2: OR 2.4, 95% CI: 1.2–4.8; >480mg/m2: OR 3.1,
95% CI 1.7–6.0), adjusted for age at diagnosis and sex. Next, a
potential cisplatin dose–response effect with TCERG1L was
estimated. By modeling cisplatin dose as a continuous variable,
effect modification (P= 0.04) was observed. After stratification, a
dose–response effect was neither observed for 360–480mg/m2
(P= 0.9), nor for >480 mg/m2 (P= 0.1) as power was lost. Future
studies with larger sample sizes are needed to accurately model
the effect of cisplatin dose.
A possible association between the SNP and age-related
hearing loss was evaluated. By contrast, rs893507 (TCERG1L) was
not associated with age-related hearing loss in a general
population (lowest P= 0.2 in the CHARGE cohort GWAS;
Supplementary Table 5 and Supplementary Fig. 1)14. Similar
results were reported in the Oxford PheWAS database for
congenital conductive and sensorineural hearing loss (P= 0.09),
and other hearing loss (P= 0.2) (http://big.stats.ox.ac.uk/variant/
10:133013187-T-C). This suggests that rs893507 (TCERG1L) is
specific for cisplatin-induced hearing loss.
The TCERG1L gene, a paralog of TCERG1, is a transcription
elongation regulator that has been described to be involved in the
pathogenesis of cancer and non-cancer-related diseases, but it has
not previously been associated with chemotherapy-induced
hearing loss. Previous studies revealed an association with
inflammatory bowel disease, as well as with colon cancer
predisposition suggesting that TCERG1L influences immunological
pathways15–17. TCERG1L is expressed in the human brain, gut,
thyroid, stem cells, adenoid, and tonsils, (http://biogps.org/
#goto=genereport&id=256536) (https://www.genecards.org/cgi-
in/carddisp. pl? gene=TCERG1)18–20, and more importantly also
in human cochlear inner and outer hair cells21 as well as murine
cochlear inner hair cells20.
Next, we performed transient TCERG1L silencing and over-
expression experiments in vitro, to examine the effect of TCERG1L
expression on cisplatin cytotoxicity and inflammatory response in
cultured human cells. We observed that modulating TCERG1L
expression significantly altered cell viability in response to
cisplatin treatment, where TCERG1L overexpression and silencing,
respectively, protected and sensitized cells to cisplatin toxicity.
Overall, modulation of TCERG1L expression significantly shifted
the cisplatin CC50 fourfold (Fig. 2a). Consistent with enhanced
resistance to cisplatin, TCERG1L overexpression reduced pro-
inflammatory IL-8 cytokine secretion in response to cisplatin
treatment; whereas TCERG1L-silencing had the opposite effect,
increasing the amount of IL-8 secreted in response to cisplatin
treatment (Fig. 2b). We also found this inverse correlation
between TCERG1L mRNA expression and pro-inflammatory
cytokine (IL-6) expression in response to cisplatin treatment by
RNA-seq in various mouse tissues (Fig. 2c, d). These data indicate
that TCERG1L function contributes to the cell’s response to
cisplatin exposure, which warrants further research and a
comprehensive examination of the genes transcriptionally
regulated by TCERG1L. In embryonic stem cells, TCERG1L
expression is subject to epigenetic regulation18. Hence, further
investigation of the interaction of this variant and epigenetic
regulation is also warranted.
Notably, we selected patients in the study cohorts with bilateral
hearing loss who had not received cranial irradiation, anticipating
the fact that cranial radiotherapy is a dominant treatment
component that may override the effect of genetic susceptibility
of cisplatin-induced ototoxicity. This effect was illustrated by the
fact that rs893507 (TCERG1L) carriership was associated with
cisplatin-induced hearing loss in non-cranial-irradiated, cisplatin
exposed childhood cancer survivors of the PCL second replication
cohort but that the significance was lost after 553 cranial-
irradiated subjects were added to the analyses (Supplementary
Table 6).
In this work, we report a genetic variant associated with
cisplatin-induced hearing loss stemming from childhood cancer
treatment. Our genetic discovery showed genome-wide signifi-
cance upon further study in additional patient cohorts including
two independent international cohorts. In total, our study
included 770 patients which is a relatively large cohort consider-
ing that childhood cancer is very rare. The strength of association
for rs893507 (TCERG1L) in a cohort of this size can be accounted
for by the observation that toxicity-associated pharmacogenomic
variants tend to have a larger effect size22. Nevertheless,
establishing worldwide collaborations to perform future studies
with even larger sample sizes remains the ideal strategy to
discover additional genome-wide significant variants that predict
adverse drug reactions in childhood cancer patients. In the
discovery cohort and second replication cohort, we were unable
to perform a robust assessment of ototoxic co-medications and
their potential influence on the strength of the TCERG1L genetic
association because retrospective patient data did not capture
complete details of these co-medications. Furthermore, eQTL
evidence for the effect of rs893507 on gene-expression levels was
not found, possibly due to limited sample sizes in these tissues.
However, eQTLs are highly tissue-specific (and often even
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Fig. 1 GWAS analysis uncovers variation at the TCERG1L locus that is associated with cisplatin-induced hearing loss. The purple diamond
(genotyped SNP) is the SNP with the lowest p-value (P < 1.0 × 10−5) in the region. The color of the remaining SNPs represents the LD of these
variants (genotyped or imputed) with the top variant. The blue lines represent recombination rates in this locus.
Fig. 2 TCERG1L expression influences in vitro and in vivo responses to cisplatin. a TCERG1L overexpression (TCERG1L) and silencing
(siTCERG1L) in HeLa cells significantly reduces and enhances cisplatin cytotoxicity, respectively, compared to empty vector (EV) or non-
targeting (siNT) controls. Cisplatin CC50 was 5.5 μM (siTCERG1L) and 18.6 μM (TCERG1L). Control conditions (EV, siNT) cisplatin CC50 was 10 μM.
***P < 0.001; ****P < 0.0001 using extra sum of squares F test; n= 21 from three independent experiments (overexpression) and n= 9 from
two independent experiments (silencing). Data are shown as the mean and standard deviation. b Pro-inflammatory IL-8 secretion at 100 μM
cisplatin was significantly reduced, or enhanced, by TCERG1L overexpression and silencing in HeLa cells compared to their respective controls.
****P < 0.0001 using two-tailed Student t-test; n= 6 or 9 from two independent experiments. Standard deviation is shown. Overexpression
and silencing experiments were performed separately but shown on the same axes for comparison in a and b. RNA expression changes of
TCERG1L (c) and IL-6 (d) across several mouse tissues following cisplatin exposure. Relative fold changes were calculated per organ against
saline-injected controls. The data set is publicly available in the NCBI Gene Expression Omnibus (GEO) under accession number GSE117167.
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situationally specific) thus the absence of an eQTL between
rs893507 and TCERG1L remains equivocal. In addition to a genetic
association, we were able to functionally implicate TCERG1L in the
development of cisplatin-induced inflammatory response and
toxicity. We observed an inverse correlation of TCERG1L with
cellular responses to cisplatin suggesting a plausible biological link
between our association results and the mechanism of cisplatin-
related hearing loss in non-cranial-irradiated subjects. The
functional data are consistent with rs893507 having a deleterious
effect on TCERG1L function.
In conclusion, the combined results of this study suggest that
cisplatin-treated, non-cranial irradiated childhood cancer patients
with a genetic intronic variant (rs893507) in TCERG1L have a 3.11
fold increased odds of developing cisplatin-induced hearing loss.
We found evidence that TCERG1L is related to direct cisplatin-
induced hearing loss in childhood cancer patients, the results of
which were strengthened through replication in two independent
replication cohorts, and biological validation in vitro. Our study
shows statistical and functional evidence for the involvement of
TCERG1L in cisplatin-induced inflammatory response and toxicity.
Even though cochlear inflammation induced by cisplatin can lead
to inner ear damage and hearing loss23, future studies are needed
to further validate the functional impact of the variant related to
hearing loss, preferably by use of human cochlear sections, and to
determine the additional (epi-)genetic regulation of the genetic
variant associated with cisplatin-induced hearing loss.
METHODS
Patients and treatment
The discovery cohort (PCL discovery cohort, D) consists of childhood
cancer patients from the PCL consortium, a multicenter cohort of
childhood cancer patients and survivors across Europe designed to
address ototoxicity, fertility impairment, and quality of life. In the current
study, 390 cisplatin-treated, non-cranial irradiated patients were included.
Subjects were diagnosed and treated for childhood cancer in Europe. A
detailed description of the PCL discovery cohort is available24. Inclusion
criteria for this study were patients: (1) diagnosed with cancer before the
age of 19 years; (2) initially treated with cisplatin, as a single platinum drug
during childhood cancer treatment, or switched from cisplatin to
carboplatin during treatment; (3) did not receive cranial or inner ear
radiation; (4) completed their chemotherapy treatment; (5) had at least one
pure tone audiometric evaluation available within two years after
completion of chemotherapy; (6) had their biomaterial (blood or saliva)
available for DNA extraction; and (7) no baseline hearing loss. Patients with
hearing loss before the start of chemotherapy and patients with initial
treatment of carboplatin were excluded. Patient data (including demo-
graphic, diagnostic, audiological, and treatment-related information) was
collected retrospectively from medical records at participating institutions
in Europe. Patients were enrolled after approval had been obtained from
local review boards and written informed consent was obtained from
patients, parents, or legal guardians. The PCL study was approved by the
local ethics committees: Kantonale Ethikkommission Bern, 362/2015;
Comitate Etico Regionale, 507REG2014; Ethical Committee University
Hospital Brno, June 11, 2016; Ethics Committee Fakultni Nemocnice v
Motole Prague, EK-1447/14; De Videnskabsetiske Komiteer Region
Hovedstaden, H-1-2014-125; Ethikkommission Medizinische Universität
Graz, 27-015 ex 14/15; Ethikkommission der Universität Ulm, 160/17;
Ethikkommission der Universität zu Lübeck, 14/181; Ethik-Kommission der
Ärztekammer Westfalen-Lippe und der Westfälischen Wilhelms-Universität
Münster, 2014-619; Medische Ethische Toetsings Commissie Erasmus MC,
MEC-2014-633; Medisch Ethische Toetsingscommissie, 2015_202 (for
centers in the Netherlands which included the Erasmus Medical Center,
Academic Medical Center, University Medical Center Groningen, and
Princess Máxima Center for Pediatric Oncology)9.
The first replication cohort (Canadian replication cohort, R1) consisted of
childhood cancer patients (n= 192) treated with cisplatin from the
Canadian Pharmacogenomics Network for Drug Safety (CPNDS), a national
research and patients care network established to reduce serious adverse
drug reactions in children (Vancouver, BC, Canada)25 (http://cpnds.ubc.ca/).
Participants in this replication cohort fulfilled all inclusion criteria of this
study as described above. In addition, cases of cisplatin-induced hearing
loss have a bilateral hearing loss only, and unilateral hearing loss cases
with normal hearing in the contralateral ear are not considered cisplatin-
induced. Demographic, diagnostic, audiological, and treatment-related
data were retrieved from medical records. The study was approved by the
research ethics board of each of the participating institutions of the
enrolled patients and written informed consent was obtained from each
patient or their legal guardian9.
An independent second replication cohort (PCL second replication
cohort, R2) consisted of childhood cancer survivors from the PCL cohort.
Participants were enrolled both retrospectively and prospectively (i.e.,
chemotherapy was started and finished during the 5-year term of PCL).
Eligibility criteria were: (1) no participation in the discovery PCL cohort (D);
(2) age at diagnosis <19 years; (3) treatment with cisplatin or cisplatin and
carboplatin; and (4) at least one pure tone audiometric evaluation available
within 5 years after the end of chemotherapy. Exclusion criteria were (1)
non-consent; (2) hearing loss before the start of platinum treatment; and
(3) cranial irradiation. Identified case-patients (i.e., hearing loss grade ≥2b
according to Muenster Classification) were matched 1:1 with controls (i.e.,
patients with Muenster grade 0–2a) for sex, age at diagnosis (tolerance 5
years), and cumulative cisplatin dose (tolerance 50mg/m2). Patients were
enrolled after approval was obtained from local review boards and written
informed consent was obtained from patients, parents, or legal guardians9.
A lookup of the GWAS hits was performed in the discovery cohort of the
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)
to evaluate a possible association between the SNP and age-related
hearing loss. This cohort on age-related hearing impairment consisted of
9,675 subjects from the general population who were all 45 years or older
at the time of the study. Phenotypes were examined that represented low/
mid (0.5, 1, and 2 kHz) and high-frequency hearing loss (at 4 and 8 kHz)
based on pure tone audiograms.
Hearing loss assessment and classification
The main endpoint of this study was hearing loss following cisplatin
treatment. Pure tone audiometry (up to 8000 Hz) was performed in all
patients after the end of platinum treatment. For all cohorts, the results of
audiological examinations were graded according to Muenster classifica-
tion (Supplementary Table 2)11. Audiogram assessors were blinded to
patient characteristics, treatment factors, and genetic data. Grading was
based on the worst ear, determined at the first measurement available
after the end of treatment. In the current study, patients who had
deleterious hearing loss grade ≥2b according to Muenster were considered
cases. Patients with Muenster grade 0−2a were assigned to the
comparison group. A comparison between subjects with Muenster grade
0 and subjects with Muenster grade ≥2b was not adequately powered due
to a lack of sufficient grade 0 subjects.
Genotyping and quality control
In the PCL discovery cohort, DNA was isolated from blood and saliva
samples. Blood samples were stored at ≤−20 °C and shipped on dry ice,
and saliva was stored and shipped at room temperature. The salting-out
method was applied to extract genomic DNA. The Illumina Infinium©
Global Screening Array (Illumina, San Diego, CA, USA) was used for DNA
genotyping. A stringent quality control protocol containing multiple filters
was applied to clean the genetic data (Supplementary Fig. 4). To remove
poorly genotyped SNPs and individuals from the data, an SNP and
individual call rate filter of 97.5% was employed. The Hardy–Weinberg
equilibrium (HWE) test with a significance level of P < 1:0  107 was used
to take out variants containing potential genotyping errors. Samples with
extreme heterozygosity, gender mismatches, and familial relationships
were removed. Thirty-two samples (8%) of non-European ancestry,
identified by genetic profile, were included. To account for genetic
ancestry, four principal components were calculated using PLINK (version
1.90). Imputations to Haplotype Reference Consortium (HRC r1.1) (http://
www.haplotype-reference-consortium.org/site) were performed using the
Michigan Imputation Server with default settings (https://imputationserver.
sph.umich.edu/index.html).
Within the CPNDS cohort, all blood and saliva samples were genotyped by
use of the Illumina Infinium© OmniExpress array. Genotyped variants
underwent stringent quality control procedures, for which the QCTOOL
(version 2), GTOOL (version 0.7.5), and PLINK (version 1.90) were used. Genetic
variants with a call rate of <95%, a minor allele frequency of <1% in both
cases and controls, and variants deviating from HWE genotype distributions
(significance level P < 1:0  106) were removed. After harmonization of the
AJM Meijer et al.
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genotype data using Genotype Harmonizer26, principal component
analyses were performed using EIGENSOFT (version 5)27,28. Sixty samples
(31%) of non-European ancestry were included. Imputation was performed
using SHAPEIT229 and IMPUTE230, using the Phase 3 1000 Genomes Project
samples as a reference (https://www.internationalgenome.org/category/
phase-3/).
In the PCL replication cohort, genotyping calls of variants replicating in
the Canadian replication cohort were validated by using TaqMan® PCR31.
GWAS and replication
Measurements were taken from distinct samples. For the GWAS analyses,
we used logistic regression models including age at diagnosis (linear term),
sex, total cumulative cisplatin dose (linear term), and four principal
components using rvtests (Supplementary Table 7). Due to the limited
sample size, we a priori determined that genome-wide significant findings
(P < 5 × 10−8) were unlikely. We therefore decided to pursue variants with
suggestive levels of association (P < 1 × 10−5) for replication.
To estimate potential cisplatin dose–response effects, we first analyzed
the association between deleterious hearing loss and cisplatin dose
continuously, as well as stratified in groups of <360, 360–480, and
>480mg/m2. Next, a potential cisplatin dose–response effect with the
genetic variant was estimated by modeling cisplatin dose as a continuous
variable as well as categorical and ran a logistic regression model including
interaction terms for the genetic variant and cisplatin dose.
Functional SNP annotations were applied by the FUMA web application,
and gene analysis and gene-set analysis were performed by MAGMA v1.6,
integrated into FUMA32.
For replication, firstly, the Canadian childhood cohort GWAS data were
used25. Secondly, a candidate SNP approach was used in the PCL adult
childhood cancer cohort of non-cranial-irradiated childhood cancer
survivors. Variants that were prioritized in the discovery analyses were
extracted from the Canadian first replication cohort genotype data. These
variants were examined for evidence of replication using logistic
regression, adjusted for age at diagnosis, vincristine, germ cell tumor
type, and principal components 1–4, using SNPTEST. Adjusted ORs and
95% CIs (two-sided) were calculated using the R package PredictABEL. P <
0.01 (0.05/7 gene variants, correcting for multiple testing by Bonferroni
correction) were considered statistically significant. Only variants replicat-
ing in the Canadian first replication cohort were candidates for replication
in the PCL second replication cohort. Association of the variant with
cisplatin-induced hearing loss was examined using logistic regression,
assuming an additive effect of the minor allele. Adjustments were made for
sex, age at diagnosis, and cumulative cisplatin dose. Data from the
discovery and replication cohorts were combined and examined using
meta-analytic approaches in R version 3.5.1, package “rmeta”33. An inverse-
variance meta-analysis was used.
Experimental validation
Functional validation experiments were performed to determine the effect
of knockdown or overexpression of TCERG1L on cisplatin cytotoxicity and
cisplatin-induced inflammatory cytokine production. We used HeLa cells as
a model of human cultured cells (ATCC catalog no. CCL-2). To determine
the impact of gene knockdown on general cell viability in the presence
and absence of varying concentrations of cisplatin in HeLa cells, MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell viability
assays were used. The cisplatin-induced inflammatory response was
assessed by interleukin-8 (IL-8) enzyme-linked immunosorbent assays
(Thermofisher). Knockdown experiments were all performed using pre-
designed TCERG1L siRNA (hs.Ri.TCERG1L.13.2; Integrated DNA Technolo-
gies) according to the manufacturer’s specifications. siRNA transfection
was performed with Lipofectamine RNAiMAX according to the manufac-
turer’s protocol (Thermofisher). Real-time quantitative PCR (RT-qPCR), using
TCERG1L specific primer-probe mix (Hs.PT.58.40562685; Integrated DNA
Technologies) showed 70% silencing efficiency of TCERG1L compared to
the non-targeting siRNA control. Overexpression experiments were all
performed using ectopic transfection of pCMV6TCERG1L (RC207369;
OriGene) using JetPrime reagent (PolyPlus) according to the manufac-
turer’s instructions.
For TCERG1L overexpression experiments cells were first seeded at
1.5–3 × 106 cells in 10 cm dishes for 24 h prior to transfection. Transfected
cells were then trypsinisized and seeded into either 96-well plates, with
5000 cells per well, or 24-well plates, with 70,000 cells per well. Newly
transferred cells were allowed to grow for another 24 h prior to cisplatin
treatment. Treatment with cisplatin proceeded for another 48 h prior to
supernatant collection and cell viability assays. For TCERG1L silencing
experiments, cells were treated as above or seeded directly into 24-well
plates prior to transfection. Cell viability curves were generated in Prism7
using non-linear curve fits normalized response and compared using Extra
sum-of-squares F-test. Relative IL-8 secretion was compared using a two-
tailed Student’s t-test.
For the expression changes of TCERG1L and IL-6 induced by cisplatin
treatment across various mouse tissues, we made use of a publicly
available dataset at the NCBI gene expression omnibus (GEO) under
accession number GSE11716734. This dataset comprises total RNA from
liver, kidney, spleen, and lung tissue specimens from 6-month-old female
mice in a pure C57Bl6/J genetic background, which were collected after 4 h
following cisplatin (10mg/kg) or saline IP injection and sequenced using
the HiSeq 4000 Illumina RNA-seq platform35. The raw data files were
downloaded and subjected to our in-house generated data analysis
pipeline. Sequence adaptors were removed from the sequence reads using
Trimmomatic version 0.39 and the trimmed reads were subsequently
aligned to the mouse genome using Star version 2.7.0f with gencode.
vM20.annotation.gtf and GRCm38. p6.genome.fa as annotation and
genome (http://gencodegenes.org/mouse/release_M20.html). Read counts
for each gene were obtained using FeatureCounts and log-fold changes
and false discovery rates were quantified using EdgeR version 3.24.3.
Visualization of the relative fold changes (cisplatin versus saline) across the
various organs was performed in GraphPad Prism version 8.4.2 (GraphPad
Software, La Jolla, CA, USA).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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